Newsletter registration

By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Where Your Profits Grow Sky High.

Swallowable cancer immune therapy being developed

Apeiron Biologics CEO Hans Loibner said: "Our concept is that we would like to develop small molecule (synthetically produced) substances which provide the immune system with specific properties.” Apeiron and Evotec established a screening system to search through a substance library containing about 100,000 substances to find an enhancing effect on immune cells. Several drug candidates were discovered within the context of the project APN411.

In contrast to monoclonal antibodies, the new drug candidates showed in laboratory tests that they could trigger several effects in the immune cells. These produce more of the anti-tumor messenger substances interleukin-2, interferon gamma and tumor necrosis factor alpha. The T-cells showed enhanced activity.  

It is also decisive for the project that the substances are small and can be very effectively produced on an industrial scale.  

Apeiron, founded by Josef Penninger, Head of the Institute for Molecular Biotechnology in Vienna (IMBA), is already involved in early clinical tests in the USA with APN401, another cancer checkpoint project. A medicine developed by Apeiron to treat brain tumors in children is awaiting approval by the European Medicines Agency (EMA). 

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

Austria Map

Find the perfect location for your company

Thanks to a fantastic mindset, our employees at the Villach site have built up a unique expertise which helps us to further strengthen our position on the global market. We fuse high-performance manufacturing with research and development in the field of power electronics. In addition to a very good cooperation with partners and networks, a well-developed landscape of 'talent factories' ranging from higher technical colleges to universities, we as a company also value the outstanding model of research promotion which exists in Austria.

Infineon

Logo Infineon
More testimonials

news from the business location Austria

Medical University of Vienna: New therapy option doubles the life span of B-cell lymphoma patients

The so-called CAR-T cell therapy is a promising option for treating around one fifth of patients with diffuse large B-cell lymphoma.

Ski Tourism as an Attractive Business Driver in Austria

Famous for its culture and unspoiled natural environment, Austria attracts vacationers and tourism companies from all over the world. One major advantage is the central location in the heart of Europe and the related good accessibility.

More news All blog posts